ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

Preventing Epilepsy Using Vigabatrin In Infants With Tuberous Sclerosis Complex

ClinicalTrials.gov ID: NCT02849457

Public ClinicalTrials.gov record NCT02849457. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 20, 2026, 6:34 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Preventing Epilepsy Using Vigabatrin In Infants With Tuberous Sclerosis Complex (PREVeNT Trial) A Randomized, Double-blind, Placebo-controlled Seizure Prevention Clinical Trial for Infants With TSC

Study identification

NCT ID
NCT02849457
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Martina Bebin
Other
Enrollment
84 participants

Conditions and interventions

Interventions

  • Delayed Vigabatrin (Placebo) Drug
  • Early Vigabatrin Drug

Drug

Eligibility (public fields only)

Age range
1 Day to 6 Months
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Nov 30, 2016
Primary completion
Apr 25, 2023
Completion
May 4, 2023
Last update posted
Aug 18, 2024

2016 – 2023

United States locations

U.S. sites
13
U.S. states
12
U.S. cities
13
Facility City State ZIP Site status
University of Alabama at Birmingham Birmingham Alabama 35233
University of California, Los Angeles Los Angeles California 90095
Stanford University Palo Alto California 94304
Children's National Medical Center Washington D.C. District of Columbia 20010
Boston Children's Hospital Boston Massachusetts 02215
Beaumont Children's Hospital Royal Oak Michigan 48073
Minnesota Epilepsy Group, PA Saint Paul Minnesota 55102
Washington University in St. Louis St Louis Missouri 63110
Duke University Durham North Carolina 37710
Cincinnati's Children Hospital Medical Center Cincinnati Ohio 45229
The Children's Hospital of Philadelphia Philadelphia Pennsylvania 19104
University of Texas Health Science Center at Houston Houston Texas 77054
Seattle Children's Hospital Seattle Washington 98105

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02849457, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Aug 18, 2024 · Synced May 20, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02849457 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →